93 results about "Single amino acid" patented technology

The invention relates to an analysis method for characterizing structures and interaction of non-denatured proteins and compounds thereof based on pulse extreme ultraviolet laser dissociation and mass spectrometry detection. Protein interacts with large and small molecules such as metal ions, drug small molecules, protein, nucleic acid or polysaccharide to form a protein compound. Natural protein and protein compound samples in a biocompatible neutral solution enter a gas phase through a non-denaturing electrospray ionization technology, then radiation excitation is performed on the natural protein and protein compound samples through pulse extreme ultraviolet laser, dissociation is induced to generate protein structure characteristic fragment ions, and finally detection and spectrogram recording are performed on the fragment ions through mass spectrum. According to the invention, the technology for characterizing the structure and interaction of the non-denatured protein and the compound of the non-denatured protein by the extreme ultraviolet band laser is realized for the first time internationally, and the method has the remarkable advantages of high sensitivity, high flux, single amino acid site resolution and the like in the aspect of researching fine structures and conformation dynamic changes of protein-protein and protein-micromolecule interaction interfaces.

The invention discloses a device and a method for designing a humanized antibody based on CDR transplantation, and a computer readable storage medium. The method comprises the following steps: replacing an antigen complementarity determining region sequence of a humanized antibody sequence with an antigen complementarity determining region sequence of a target antigen heterologous antibody to obtain a CDR region transplantation antibody; the method comprises the following steps: performing single amino acid reverse mutation on different amino acid sites of a CDR region transplantation antibody and a heterologous antibody, and comparing structural difference scores of protein three-dimensional structures before and after mutation; retaining the single amino acid reverse mutation site with the structural difference score less than or equal to 1, and finally obtaining the CDR transplanted humanized antibody of the target antigen. According to the method, the similarity of heterologous antibody and human antibody sequences can be increased, the immunogenicity of the target antigen human antibody is reduced, and the affinity is maintained.

The invention provides Cas12a mutants from Murraya bovis AAX08, and methods of using the Cas12a mutants. The Mb2Cas12a mutant comprises a single amino acid substitution, a plurality of amino acid substitutions, a structural domain exchange, or all of the above. Compared with a wild type moraxella bovine eye AAX08Cas12a enzyme, the mutants have enhanced DNA (Deoxyribose Nucleic Acid) lysis activity in plants.

The present disclosure relates to a codon optimization technique based on token classification. In a model training phase, a collected protein sequence is tokenized by using a single amino acid as a token, and a nucleic acid sequence encoding a protein and corresponding to the protein sequence is tokenized by using a single codon as a token; a plurality of different synonymous codons in the tokenized nucleic acid sequence encoding the protein and corresponding to a single amino acid in the tokenized protein sequence are sorted in a descending order of frequency of occurrence in an expression system of the protein, and a classification label is set, thereby training a natural language model. In a prediction phase of the nucleic acid sequence encoding the protein, a protein sequence to be subjected to codon optimization is tokenized. The tokenized protein sequence is input into the trained natural language model to predict a classification label of a synonymous codon corresponding to a single amino acid in the tokenized protein sequence. An optimized nucleic acid sequence is obtained on the basis of a mapping relationship between the synonymous codon and the classification label thereof.

The invention discloses a production process of melittin, belongs to the technical field of polypeptide synthesis, and particularly relates to a preparation method of melittin, which comprises the following steps: synthesizing melittin-peptide resin by adopting a solid-phase synthesis method according to the sequence of melittin sequences, and cutting and purifying to obtain melittin; in the solid-phase synthesis method, amino acid reagents are coupled one by one or at least more than one melittin peptide fragment and a single amino acid reagent are adopted for coupling, and the number of amino acids in the melittin peptide fragment is 4-8. The melittin peptide fragment is synthesized by adopting a liquid-phase synthesis carrier, and the liquid-phase synthesis carrier is obtained by synthesizing 2, 4-dihydroxy benzaldehyde, 1, 4-dibromocyclohexane and diethyl bromomalonate and reducing the 2, 4-dihydroxy benzaldehyde, the 1, 4-dibromocyclohexane and the diethyl bromomalonate.

The invention belongs to the technical field of gene engineering and cell transformation, and discloses a gene engineering construction method and application of anti-apoptosis human mesenchymal stem cells. Through HDAC1 K412 site specific lactic acid mutation, breakthrough improvements are realized: for example, CRISPR-Cas9-mediated accurate gene editing is utilized, only a single amino acid site is changed, that is, K412R mutation simulates persistent lactic acid, and whole genome apparent modification disturbance can be avoided; the modification does not depend on an exogenous metabolic substrate, and the negative feedback effect of traditional metabolic intervention is overcome; the mutant continuously inhibits a P53 apoptosis pathway, so that the oxidative stress mediated apoptosis resistance of the MSC is remarkably improved. According to the design concept of one target spot and one regulation, the core contradiction that long-term effectiveness and specificity cannot be considered in the prior art is fundamentally solved, and a brand new normal form is provided for stem cell treatment.

The invention discloses thymus dependent lymphocyte antigen epitope peptide of hepatitis B virus antigen and application, and belongs to the field of medical immunology and infectious pathology. The thymus dependent lymphocyte antigen epitope peptide of the hepatitis B virus antigen is characterized in that the amino acid sequence of the epitope peptide comprises any one or more of the following: SPTVWLSVI; an LPLLPIFFCL (low-performance liquid chromatography- CPTVQASKL, and CPTVQASKL; an LPSDFFPSI (Liquefied Peptide The amino acid sequence is an amino acid sequence obtained by removing or replacing a single amino acid of the amino acid sequence. The epitope peptide disclosed by the invention can be specifically combined with cytotoxic thymus dependent lymphocytes to stimulate the cytotoxic thymus dependent lymphocytes to activate, proliferate and differentiate, so that the immune effect of resisting the hepatitis B virus is exerted; the antigen peptides can be used for preparing therapeutic and prophylactic vaccines for hepatitis B virus infection, can also be used for preparing detection reagents for detecting hepatitis B virus specific cytotoxic thymus dependent lymphocytes, and have potential application value in prevention, treatment and diagnosis of hepatitis B.

The invention belongs to the technical field of biology, and particularly relates to a hybridoma cell strain capable of secreting a clostridium perfringens ETX monoclonal antibody with neutralizing activity and application of the hybridoma cell strain. On the basis of natural toxin, an indirect ELISA (enzyme-linked immunosorbent assay) detection method is established by utilizing a non-toxic ETX single amino acid site protein mutant, and a series of hybridoma cell strains secreting an anti-clostridium perfringens ETX monoclonal antibody are screened; the hybridoma cell strain can stably and efficiently secrete a monoclonal antibody with neutralizing activity and a monoclonal antibody without neutralizing resistance respectively, and large-scale batch production can be realized. According to the present invention, the clostridium perfringens ETX monoclonal antibody is firstly utilized to establish the ETX antigen ELISA detection method, and the method has characteristics of simple sample operation, low cost, rapid reaction, strong specificity and the like, can provide the reference for the diagnosis of clostridium perfringens, and provides the basis for the research of the related vaccine potency test substitution method.

The invention discloses a method for detecting polypeptide sequence difference and post-translational modification thereof based on a nanopore system, the nanopore system is constructed in the method, and the nanopore system comprises an alpha-hemolysin nanopore and octa-amino modified gamma-cyclodextrin embedded in the nanopore; the amino acid sequence of the alpha-hemolysin nanopore comprises mutation sites M113R and T145R, and the alpha-hemolysin nanopore is characterized in that the alpha-hemolysin nanopore According to the detection method, polypeptide with negative charges enters a nanopore under the driving of external voltage, an ion current blocking signal is recorded, and the polypeptide sequence difference and post-translational modification are analyzed according to blocking amplitude, duration, noise characteristics and event frequency. The method can detect a peptide chain with the length of 2-10 amino acid residues, can distinguish the post-translational modification state in homopolypeptide composed of 4-10 amino acids and polypeptide by single amino acid resolution, and can be used for protein enzyme digestion product analysis, oligopeptide drug detection and rapid polypeptide identification under the condition of no mass spectrum.

The invention discloses thymus dependent lymphocyte antigen epitope peptide of hepatitis B virus antigen and application, and belongs to the field of medical immunology and infectious pathology. The invention discloses thymus dependent lymphocyte antigen epitope peptide of hepatitis B virus antigen. The amino acid sequence of the epitope peptide comprises any one or more of SYVNVNMGL, SYVNVNMGL, SYVNVNMGL, SYVNVNMGL, SYVNVNMGL LATWVGSNL (Lattice, Attention, an RRMETTVNA (radio frequency identification tag); mAARVCCQL is used as a template; the amino acid sequence is an amino acid sequence obtained by removing or replacing a single amino acid of the amino acid sequence. The epitope peptide disclosed by the invention can be specifically combined with cytotoxic thymus dependent lymphocytes to stimulate the cytotoxic thymus dependent lymphocytes to activate, proliferate and differentiate, so that the immune effect of resisting the hepatitis B virus is exerted; the antigen peptides can be used for preparing therapeutic and prophylactic vaccines for hepatitis B virus infection, can also be used for preparing detection reagents for detecting hepatitis B virus specific cytotoxic thymus dependent lymphocytes, and have potential application value in prevention, treatment and diagnosis of hepatitis B.

The present application relates to a kind of escherichia coli speC ornithine decarboxylase mutant and its application.The mutant is obtained by single amino acid replacement, replacement site is K574A, K574H or S687A, with wild-type SpeC ornithine decarboxylase derived from escherichia coli as parent.Compared with wild type, the specific enzyme activity of the above mutant is increased by 123.33%, 17.27% and 43.64% respectively, wherein the specific enzyme activity of K574A mutant is 7.37 U / mg, about 2.23 times of wild type.The present application also provides the gene encoding the mutant, recombinant expression vector, recombinant host cell and the method for preparing 1,4-butanediamine in vitro catalysis using the mutant.The mutant can efficiently catalyze L-ornithine decarboxylation to generate 1,4-butanediamine in the presence of pyridoxal phosphate, and has good application prospect in the field of enzyme synthesis of 1,4-butanediamine.

The invention relates to the technical field of biology, in particular to a protective monoclonal antibody targeting BCG (bacillus calmette guerin) BCG3965 as well as a preparation method and application of the protective monoclonal antibody. The antibody or an antigen binding fragment comprises a CDR sequence selected from at least one of the following sequences or a sequence with one amino acid substituted, deleted or increased: a heavy chain variable region CDR sequence: SEQ ID NO: 3-5; and the light chain variable region CDR sequences are as shown in SEQ ID NO: 7-9. The monoclonal antibody 5F10 shows efficient antituberculous activity in vivo and in vitro through specific targeting of BCG3965 protein on the surface of mycobacterium tuberculosis, mainly including the aspects of remarkably enhancing the phagocytosis of macrophages on tubercle bacillus, inhibiting tubercle bacillus growth and the like, and in addition, the monoclonal antibody 5F10 is clear in sequence and structure, easy to develop and modify, and capable of being used for preparing antituberculous drugs for treating mycobacterium tuberculosis. The monoclonal antibody 5F10 disclosed by the invention has the advantages that the monoclonal antibody 5F10 is not easy to induce pathogens to generate drug resistance by an immune-mediated treatment mechanism, and the monoclonal antibody 5F10 is applied to prevention and treatment of tuberculosis, not only provides a new choice for treatment of tuberculosis, but also provides an important technical basis for response of drug-resistant strains, development of diagnostic reagents, vaccine development and the like, and is wide in application prospect.

The invention relates to the technical field of genetic engineering, in particular to a mutant of HC-Pro protein and application of the mutant to prevention and treatment of papaya malformed mosaic virus. Through papaya field virus disease investigation, a low virulent strain PLDMV-R165I is identified and found on a papaya plant without symptom infection of PLDMV, and single amino acid mutation of the 165th amino acid of the PLDMV HC-Pro multifunctional protein is found after the amino acid full-length sequence of the low virulent strain PLDMV-R165I is compared with the amino acid full-length sequence of a wild type high virulent strain PLDMV. It is further verified that after mutation of the site, replication of the virus is affected, the RNA silencing inhibition activity of HC-Pro is weakened, accumulation of the virus in the papaya body is reduced, and the site is a newly-found key amino acid for determining PLDMV disease generation and virus replication and accumulation.

To provide an antibody-drug conjugate having a linker constituent of a new class.SOLUTION: Provided is a novel cell-binding agent-maytansinoid conjugate having a self-sacrificial peptide linker, more specifically, a conjugate of formula (I) or a pharmaceutically acceptable salt thereof. [In the formula, CB denotes a cell-binding agent; L2 is absent or a spacer; A denotes a peptide containing a single amino acid residue or 2 to 20 amino acid residues; R1 and R2 denote each independently H or C1-3 alkyl; L1 denotes a spacer; D-L1-SH denotes a cytotoxic drug; and q denotes an integer of 1 to 20]SELECTED DRAWING: None

The invention discloses a thymus dependent lymphocyte antigen epitope peptide of a liver cancer associated antigen AFP and application, and belongs to the field of medical immunology and oncology. The invention discloses a thymus dependent lymphocyte antigen epitope peptide of a liver cancer associated antigen AFP. The amino acid sequence of the epitope peptide comprises any one or more of the following: KWVESIFLI; tFMNKFIYEI, fLYAPTILL is used as a template; kYIQESQAL is selected from the group consisting of the following components; the amino acid sequence is an amino acid sequence obtained by removing or replacing a single amino acid of the amino acid sequence. The epitope peptide disclosed by the invention can be specifically combined with cytotoxic thymus dependent lymphocytes to stimulate the cytotoxic thymus dependent lymphocytes to activate, proliferate and differentiate, so that an anti-tumor immune effect is exerted; the antigen peptides can be used for preparing therapeutic and prophylactic vaccines for liver cancer, can also be used for preparing quantitative detection reagents for detecting specific T cells of liver cancer related antigen AFP, and have potential application value in prevention, treatment and diagnosis of liver cancer.

The application discloses a protein post-translational modification prediction method based on multi-head attention, and belongs to the technical field of biological information, and comprises the following steps: preprocessing protein sequences with post-translational modification annotation information to obtain a legal character set, a second protein sequence data set and a benchmark data set; obtaining three kinds of vocabulary tables based on the legal character set; performing multi-scale division on protein sequence samples in the second protein sequence data set to obtain a single amino acid scale data set, a dipeptide scale data set and a tripeptide scale data set; training a corpus by using a Skip-gram model structure to obtain three kinds of word vector models; performing label prediction on protein sequence fragments of the benchmark data set by using a multi-head attention model to obtain protein sequence fragment prediction results; and the multi-scale word vector is used to comprehensively utilize polypeptide composition information in the original protein sequence, and the dependence on biological feature engineering is reduced.

Methods of generating a limb-girdle muscular dystrophy (LGMD) functional score, as well as methods of predicting and treating LGMD are provided. The present disclosure teaches methods of generating a LGMD functional score through single amino acid mutagenesis and deep mutation scanning (DMS) data including a mutant reads high expression and a mutant reads low expression.

The application discloses a protein secondary structure prediction method based on single-amino acid sequence characteristics, and belongs to the field of bioinformatics. The application solves the problem that the prediction effect of a model obtained by using an existing method is poor due to the limitation of evolutionary information feature acquisition and the fact that the model ignores the interdependent relationship between secondary structure labels in an amino acid sequence. In the feature processing stage, the application fuses feature representations generated by a protein language model and features obtained by using a hybrid coding mode of word embedding and position embedding. The fused features contain rich evolutionary information and fully acquire position information of amino acid residues in the sequence and the dependent relationship between the amino acid residues. The fused features are sequentially output through a Transformer encoder, a CNN and a BiLSTM to output global feature information, and the interaction between secondary structures of proteins in the sequence is considered by introducing a CRF, so that the protein secondary structure prediction accuracy is ensured. The method of the application can be applied to protein secondary structure prediction.

Described is a method for treating or preventing an infection, such as an infection associated with Staphylococcus epidermidis such as a Health-Care Associated infection, a wound, a sore, an ulcer, a burn. The method includes applying a treatment preparation to a treatment site, the treatment preparation has a first component having a single amino acid, said single amino acid being leucine, and a second component having an active chlorine compound.

The invention provides an acyl carrier protein ACP65-74 and a preparation method of the acyl carrier protein ACP65-74. The preparation method comprises the following steps: carrying out deprotection and first washing on resin, and sequentially carrying out in-situ activation reaction on the resin by taking one amino acid as a unit according to the sequence of an amino acid sequence of acyl carrier protein ACP65-74 as shown in SEQ ID NO: 1; the in-situ activation reaction comprises the following steps: S1, carrying out coupling reaction on a single amino acid solution, an activating agent, a condensing agent and resin, and when the change of the conductivity of the reaction solution is less than 1%, filtering and carrying out secondary washing; and S2, sequentially carrying out deprotection and third washing on the resin subjected to the step S1. On-line monitoring is carried out on the process of solid-phase synthesis of the ACP65-74 from the polypeptide, so that the reaction efficiency can be improved, the purity of the product is improved, unnecessary waste in the reaction process is reduced, and the synthesis cost of the acyl carrier protein ACP65-74 is saved.

The present invention discloses a method for liquid chromatography tandem mass spectrometry for rapid analysis of multiple amino acids in plasma. The method comprises the following steps: S1. Preparation of an amino acid standard curve working solution, including accurately weighing powders of 26 amino acid standards respectively, adding them to pure water, and fully mixing to prepare single amino acid stock solutions of 10 mg / mL. The present invention relates to the technical field of liquid chromatography tandem mass spectrometry for simultaneous detection of multiple amino acids. For the method of liquid chromatography tandem mass spectrometry for rapid analysis of multiple amino acids in plasma, after performing a protein precipitation reaction on the plasma, the treated sample can be used for liquid chromatography tandem mass spectrometry analysis. Combining with the pretreatment mode of 96-well plates, the pretreatment process of 96 plasma samples only takes 40 minutes. Additionally, by using an optimized combination of mobile phase and chromatographic column, the sample injection analysis time is only 10 minutes. The processing scheme of this device is simple and efficient, and no derivatization reaction is required.

The invention relates to a transmembrane polypeptide with neuroprotection and application thereof, the transmembrane polypeptide comprises 2-4 amino acids, and the amino acid sequence comprises at least one unmodified amino acid with neuroprotection and leucine connected with at least one peptide terminal as a transmembrane carrier; wherein at least one of the peptide bonds connected with the unmodified amino acid is a protease hydrolysis site, so that the unmodified amino acid can be hydrolyzed into free single amino acid. Experiments prove that the leucine can be used as a carrier for penetrating the blood brain barrier, carries amino acid which is difficult to penetrate through BBB and has neuroprotection, penetrates through the blood brain barrier to enter the brain, is hydrolyzed into corresponding specific amino acid in the brain, plays a role in protecting the brain, can be applied to preparation of medicines for treating nervous system diseases, and has broad application prospects. The compound is especially used for preparing a neuroprotective drug for treating brain injury.

The invention discloses a thymus dependent lymphocyte antigen epitope peptide of a liver cancer associated antigen AFP and application, and belongs to the field of medical immunology and oncology. The invention relates to a thymus dependent lymphocyte antigen epitope peptide of a liver cancer associated antigen AFP. The amino acid sequence of the epitope peptide comprises any one or more of AQFVQEATYK, AQFVQEATYK, AQFVQEATYK and AQFVQEATYK. FLYAPTILLW, FLYAPTILLW; sLLNQHACAV (Solvent Level Normal The amino acid sequence is an amino acid sequence obtained by removing or replacing a single amino acid of the amino acid sequence. The epitope peptide disclosed by the invention can be specifically combined with cytotoxic thymus dependent lymphocytes to stimulate the cytotoxic thymus dependent lymphocytes to activate, proliferate and differentiate, so that an anti-tumor immune effect is exerted; the antigen peptides can be used for preparing therapeutic and prophylactic vaccines for liver cancer, can also be used for preparing quantitative detection reagents for detecting specific T cells of liver cancer related antigen AFP, and have potential application value in prevention, treatment and diagnosis of liver cancer.

The invention belongs to the technical field of carbon dioxide fixation. The invention provides a biological carbon sequestration enzyme mutant. The biological carbon sequestration enzyme mutant is obtained after threonine at the 398th site of RPE Rubisco is mutated; the amino acid sequence of the RPE Rubisco is as shown in SEQ ID NO. 1 in a sequence table. The threonine mutation is that threonine is mutated into alanine. According to the invention, through mutation of a single amino acid, the catalytic efficiency of Rubisco is successfully improved, and especially, the turnover number of enzyme is greatly increased and reaches 35.84 S <-1 >. Through reasonable structural design, the trade-off effect between kcat and km is successfully avoided, so that the Rubisco keeps high CO2 affinity while the activity is improved. The method is simple, is suitable for design and modification of other carboxylases, and has a wide application prospect.

The invention belongs to the technical field of biology, and particularly relates to a hybridoma cell strain capable of secreting a clostridium perfringens ETX monoclonal antibody with neutralizing activity and application of the hybridoma cell strain. Natural ETX is used as an immunizing antigen for the first time, a non-toxic single amino acid ETX mutant is used as a coating antigen, and a cell neutralization test of clostridium perfringens natural toxin and a serum neutralization test of mice are combined to screen the monoclonal antibody hybridoma cell strain with neutralization activity. The screened hybridoma cell strain can stably and efficiently secrete a monoclonal antibody with neutralizing activity and a monoclonal antibody without neutralizing resistance respectively, and large-scale batch production can be realized. According to the present invention, the clostridium perfringens ETX monoclonal antibody is firstly utilized to establish the ETX colloidal gold detection method, and the method has characteristics of simple sample operation, low cost, rapid reaction, strong specificity and the like, and can provide the basis for the rapid diagnosis of clostridium perfringens disease.

A linker, comprising an amino acid unit (RL). The RL comprises -Val-Ala-Q-Gly-Phe-Gly-, wherein Q is a bond, a single amino acid or a dipeptide. By optimizing a polypeptide sequence, the purpose of more effectively releasing small molecule drugs in tumor cells by ADC drugs is achieved. In addition, the present invention further relates to linker drug containing the above-mentioned linker, a conjugate, and the use of the linker drug and the conjugate.

The application provides a polypeptide and protein sequencing method, a kit and application. The polypeptide sequencing method comprises the following steps: S1, attaching a target polypeptide to a nanopore; S2, introducing a recognition molecule specifically recognizing a terminal amino acid of the target polypeptide into a nanopore sequencing system; under the action of an electric field, the detection of the terminal amino acid of the target polypeptide is realized by utilizing the electric signal change generated in the binding and dissociation process of the recognition molecule and the target polypeptide. By utilizing the unique electric signal change generated in the binding and dissociation process of the recognition molecule and the terminal amino acid of the target polypeptide, the detection of a single amino acid is realized.

The invention provides a synthetic method of bionic collagen hexapeptide, and belongs to the technical field of biological medicine. According to the method, single amino acid is used as a raw material, condensation, selective deprotection and fragment condensation are sequentially carried out through an activated ester method, and finally the bionic collagen hexapeptide shown in the formula (I) is prepared. According to the method, an expensive solid-phase synthesis carrier is abandoned, the raw material cost is low, a liquid-phase synthesis route is simple and convenient to operate, large-scale amplification is easy, side reactions are effectively controlled through a reasonable protection strategy, the product purity is high, and an efficient and economical preparation way is provided for development of related biological materials. Formula (I).

The invention discloses a thymus dependent lymphocyte antigen epitope peptide of a liver cancer associated antigen AFP and application, and belongs to the field of medical immunology and oncology. The invention discloses a thymus dependent lymphocyte antigen epitope peptide of a liver cancer associated antigen AFP. The amino acid sequence of the epitope peptide comprises any one or more of the following: AITVTKLSQK; yLQNAFLVA (Yttrium Laboratory Quantitative FSDDKFIFHK, FSDDKFIFHK The amino acid sequence is an amino acid sequence obtained by removing or replacing a single amino acid of the amino acid sequence. The epitope peptide disclosed by the invention can be specifically combined with cytotoxic thymus dependent lymphocytes to stimulate the cytotoxic thymus dependent lymphocytes to activate, proliferate and differentiate, so that an anti-tumor immune effect is exerted; the antigen peptides can be used for preparing therapeutic and prophylactic vaccines for liver cancer, can also be used for preparing quantitative detection reagents for detecting specific T cells of liver cancer related antigen AFP, and have potential application value in prevention, treatment and diagnosis of liver cancer.

A lipid-vitamin conjugate based on an amino acid structure and a synthesis method therefor. The head of the lipid-vitamin conjugate consists of a single amino acid or a plurality of amino acids, and the tail thereof consists of a hydrophobic vitamin and a fatty chain. The molecular weight of the amino acid-based lipid-vitamin conjugate is 1000-2000 Da. The synthesis method is a solid-phase synthesis method based on polypeptide synthesis, and the method comprises: first attaching the carbon terminus of an amino acid to a 2-chlorotrityl chloride resin, then carrying out condensation-washing-deprotection-washing cycle synthesis, and finally, coupling a vitamin and a fatty chain to the nitrogen terminus to obtain a lipid-vitamin conjugate based on an amino acid structure. The synthesized lipid-vitamin conjugate is cleaved from the resin by means of a cleavage solution, and soluble by-products are removed from the organic solvent by means of a non-polar solvent. The method features ease of operation, high product purity, minimal complex factors requiring control, and high reproducibility.